구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Cosentyx (secukinumab) | Bimzelx (bimekizumab) | AIN457 (secukinumab) |
Overview Company | Novartis | UCB | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A | IL-17A / IL-17F | Psoriatic Arthritis |
Overview Indication | Psoriasis, PsA, AS, nr-axSpA, HS | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — |
Positioning Known limitation | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — |
Positioning Development positioning | — | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — |
MoA Mechanism | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI, ASAS response, radiographic progression in SpA. | PASI/IGA response, hs-CRP in axial disease. | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 31 h | ~23 days | 31 h |
PK/PD Species | Mouse, Human, PASI75/90, IL-17A suppression | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | Rat, Human |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP, In vitro | Human, Rat |
PK/PD Experiment | PD | pd | PD |
Toxicology Species | Mouse, Human | Cynomolgus monkey | Rat, Human |
Toxicology Animal (cat.) | — | — | Human, Rat |
Toxicology Major finding | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | 44% | — | 9% |
Clinical PASI75 | — | PASI 100 than secukinumab at week 16 and mai | — |
Clinical Result source | ClinicalTrials.gov NCT04300296 | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04300296 | NCT03536884 | NCT03131570 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Cosentyx (secukinumab) | Bimzelx (bimekizumab) | AIN457 (secukinumab) |
Overview Company | Novartis | UCB | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-17A | IL-17A / IL-17F | Psoriatic Arthritis |
Overview Indication | Psoriasis, PsA, AS, nr-axSpA, HS | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres | IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance. | — |
Positioning Known limitation | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 | Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes. | — |
Positioning Development positioning | — | Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents. | — |
MoA Mechanism | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. | Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | PASI, ASAS response, radiographic progression in SpA. | PASI/IGA response, hs-CRP in axial disease. | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 31 h | ~23 days | 31 h |
PK/PD Species | Mouse, Human, PASI75/90, IL-17A suppression | Cynomolgus monkey, PASI 90/100, HiSCR in HS, ASAS40 in axSpA | Rat, Human |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP, In vitro | Human, Rat |
PK/PD Experiment | PD | pd | PD |
Toxicology Species | Mouse, Human | Cynomolgus monkey | Rat, Human |
Toxicology Animal (cat.) | — | — | Human, Rat |
Toxicology Major finding | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. | Oral candidiasis is the signature toxicity of IL-17F co-blockade and occurs in roughly 10–20% of patients. Upper respiratory infection is common; inflammatory bowel disease requires monitoring. | Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review.. To summarize recent literature evaluating treatment outcomes in adults with plaque psoriasis who switched to brodalumab from a different biologic because of treatment failure (inadequate initial response/loss of an adequate initial response) and/or adverse events. Relev… |
Clinical Selected reported efficacy | 44% | — | 9% |
Clinical PASI75 | — | PASI 100 than secukinumab at week 16 and mai | — |
Clinical Result source | ClinicalTrials.gov NCT04300296 | BE RADIANT (NCT03536884) / BE VIVID / BE SURE | ClinicalTrials.gov NCT03131570 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04300296 | NCT03536884 | NCT03131570 |
추천 비교
추천 비교